Home » Newsletters » BioWorld Science

BioWorld Science

March 12, 2018

View Archived Issues

Sigilon Therapeutics' SIG-003 awarded EMA ATMP designation

iOx Therapeutics receives investment from Portage Biotech

Novel algorithm using proteotoxic biomarkers to discriminate between ASD and healthy subjects

Phase II data presented from the STOP-AKI trial of recAP in sepsis-associated acute kidney injury

Solifenacin oral suspension for pediatric patients approved in Europe

First-in-human results for Progenza in patients with knee osteoarthritis

Polyphor reports outcome of end-of-phase I meeting with FDA on balixafortide

Aradigm submits MAA for Linhaliq in non-cystic fibrosis bronchiectasis

CHRIST University patents new ER-targeting conjugates for cancer

Nanchang Helioeast Pharmaceutical presents new TKIs for cancer

Voyager Therapeutics reports longer-term data from phase Ib study of VY-AADC in Parkinson's disease

Biohaven restructures license agreement with Bristol-Myers Squibb

Medivir discloses novel compounds for RSV infection

IO Biotech collaborates with Merck & Co. to study IO-102 with pembrolizumab for NSCLC

Deinove enters antibiotic research collaboration with Naicons

FDA grants regenerative medicine advanced therapy designation to AmnioFix

BC-007 reduces autoantibodies against G-protein coupled receptors in phase I study

Seattle Genetics' acquisition of Cascadian Therapeutics complete

Kezar Life Sciences initiates phase I/II study of KZR-616 in SLE

Arrowhead opens enrollment in phase I study of ARO-AAT

Immutep and Merck & Co. to collaborate on phase II study of eftilagimod with pembrolizumab

CSL-112 found safe in patients with renal impairment after AMI

Diamyd Medical offers update from DIAGNODE-1 study of Diamyd diabetes vaccine

FDA awards fast track designation to NovaBiotics' Lynovex

Atrial fibrillation burden not reduced by XEN-D0103 in patients with pacemakers

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...